Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00354835 · OUTCOME

Toxicity With GSTA1 and CYP2C9 Genotypes

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma · Source last updated 2023-01-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
During the study

What was measured

Incidence of toxicity related to VAC treatment in patients with GSTA1 and CYP2C9 genotypes.

Analysis population: The analysis was abandoned due to low incidence of toxicity. Data were not collected.

Groups in this outcome

Vincristine, Dactinomycin, Cyclophosphamide (VAC)

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Incidence of toxicity related to VAC treatment in patients with GSTA1 and CYP2C9 genotypes.
groups
  1. id
    OG000
    title
    Vincristine, Dactinomycin, Cyclophosphamide (VAC)
population Description
The analysis was abandoned due to low incidence of toxicity. Data were not collected.
reporting Status
POSTED
time Frame
During the study
title
Toxicity With GSTA1 and CYP2C9 Genotypes
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice